{"id":"placebo-for-naftopidil","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert substances used as controls in clinical trials to establish the efficacy of an active drug by comparison. They allow researchers to distinguish between the therapeutic effects of the investigational drug (naftopidil in this case) and effects due to patient expectation or natural disease progression. The placebo arm is essential for demonstrating that any observed clinical benefit is attributable to the active drug rather than placebo response.","oneSentence":"A placebo control contains no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:19.491Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 trial of naftopidil (likely lower urinary tract symptoms or benign prostatic hyperplasia, based on naftopidil's known indication)"}]},"trialDetails":[{"nctId":"NCT01952314","phase":"PHASE3","title":"Medical Expulsive Therapy for Ureter Stone Using Naftopidil","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-05","conditions":"Ureter Stones","enrollment":150},{"nctId":"NCT01959074","phase":"PHASE3","title":"The Effect of Naftopidil for the Double-J Stent Discomfort","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-05","conditions":"Disorder of Urinary Stent","enrollment":100},{"nctId":"NCT02011737","phase":"PHASE4","title":"Naftopidil 75mg for Improving Clearance of Urinary Stones","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2014-02","conditions":"Kidney Calculi, Ureter Calculi","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Naftopidil","genericName":"Placebo for Naftopidil","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo control contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in phase 3 trial of naftopidil (likely lower urinary tract symptoms or benign prostatic hyperplasia, based on naftopidil's known indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}